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of severe cardiac dysfunction, episodes of fluid 
retention, severe impairment of functional ca‑
pacity, and history of 1 or more hospitalizations 
for HF in the past 6 months, despite optimized 
medical, surgical, and device therapy.1,8
Despite recent advances in the treatment of 
end ‑stage HF, morbidity and mortality rates are 
still unacceptably high. Effective risk stratification 
and evaluation of prognostic markers are the key 
elements of the management of HF. The precise 
identification of HF patients at the highest risk 
of disease progression or death would enable phy‑
sicians to intensify medical, surgical, and device 
therapy, including mechanical circulatory sup‑
port implantation and heart transplantation, thus 
improving the prognosis of these individuals.1,6 
In addition, estimating prognosis for morbidity 
and mortality may help patients and their fami‑
lies understand the nature of illness and the rea‑
sons for a referral to supportive or palliative care 
in selected cases.1,6 Many univariate predictors of 
poor prognosis in HF have been identified, includ‑
ing high New York Heart Association functional 
class, reduced left ventricular ejection fraction, 
abnormal right ventricular function, concomi‑
tant diastolic dysfunction, low peak oxygen con‑
sumption during cardiopulmonary exercise test‑
ing, and signs of reduced tissue perfusion (eg, low 
mean arterial pressure, renal dysfunction, and 
neurohormonal activation).1,6,9
It is well known that comorbidities influence 
the pathophysiology, management, and progno‑
sis of advanced HF, contributing to increased mor‑
bidity and mortality.1-6 Murad et al10 demonstrated 
that 60% of elderly patients with HF had at least 3 
comorbidities, while only 2.5% of them had none. 
Renal and liver dysfunction significantly increases 
mortality associated with HF.6 The pathophysiology 
of cardiorenal syndrome in end ‑stage HF involves 
neurohormonal and hemodynamic imbalance be‑
tween the heart and kidneys.6 It results in the stim‑
ulation of the sympathetic nervous system and 
activation of the renin–angiotensin–aldosterone 
Heart failure (HF) is a complex and heterogeneous 
clinical syndrome, which is characterized by in‑
creasingly high prevalence, unfavorable progno‑
sis, and poor quality of life.1-3 It is estimated that 
HF affects approximately 38 million adults world‑
wide, including at least 15 million Europeans.2,4 
In Poland, about 600 000 to 700 000 people suf‑
fer from HF.5 Data from cohort studies showed 
that from 5% to 10% of patients with HF devel‑
op an advanced stage of the disease with an av‑
erage life expectancy of 6 to 12 months.4 In pa‑
tients with end ‑stage HF (advanced, stage D), 
treatment options are relevantly limited, mor‑
bidity is usually progressive, and survival is ex‑
tremely short with a 1 ‑year mortality rate of ap‑
proximately 50%.6,7 In the REMATCH multicenter 
trial (Randomized Evaluation of Mechanical As‑
sistance for the Treatment of Congestive Heart 
Failure), patients with end ‑stage HF who were 
ineligible for heart transplantation showed a 
mortality rate of 75% in the first year and vir‑
tually no survival at 2 years of follow ‑up.6 Sim‑
ilarly, in the INTREPID study (Investigation of 
Nontransplant ‑Eligible Patients Who Are Ino‑
trope Dependent), patients with end ‑stage HF 
on optimal pharmacological treatment had sur‑
vival rates of 22% at 6 months and 11% at 1 year.6 
In addition, inotrope‑dependent patients with 
end‑stage HF had the most unfavorable progno‑
sis and survival rate of only 6% at 1 year.6
Various definitions and criteria of diagnosis 
have been proposed so far for advanced HF.1,6-8 
Unfortunately, there is no unique parameter to 
define this clinical condition. It was postulat‑
ed that escalation of diuretic doses, intolerance 
or reduction of doses of neurohormonal antag‑
onists, refractory arrhythmias, development of 
end ‑organ dysfunction, malnutrition/cardiac ca‑
chexia, and repeated hospitalizations, all indicat‑
ed advanced HF and refractoriness to traditional 
therapies.6 The European Society of Cardiology de‑
fines advanced HF as a chronic clinical syndrome 
with severe symptoms of HF, objective evidence 
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risk calculator, and the Heart Failure Survival 
Score (HFSS).12,13 The SHFM estimates the ef‑
fect of adding newer HF therapies (eg, ultrafil‑
tration, implantable cardioverter defibrillator/
cardiac resynchronization therapy, and left ven‑
tricular assist devices) on mortality, but it may 
overestimate survival, especially in patients with 
severe HF.12,13
Recently, numerous studies have shown that 
the Model for End ‑Stage Liver Disease (MELD) 
score and its variants (TABLE 1) constitute valu‑
able tools for estimation of cardiorenal and car‑
diohepatic interactions and predict mortali‑
ty in individuals with HF, after Fontan surgery, 
with end ‑stage liver disease, and in cirrhotic pa‑
tients undergoing cardiac and noncardiac pro‑
cedures.12-14 The classic MELD score uses 3 non‑
cardiac biomarkers that reflect the severity of liv‑
er (international normalized ratio, serum biliru‑
bin) and renal (serum creatinine) dysfunction.12-14 
In individuals receiving vitamin K antagonists 
(eg, warfarin) due to concomitant atrial fibril‑
lation/flutter, the use of the “modified MELD” 
(modMELD) or “MELD excluding INR” (MELD ‑XI) 
scoring systems is recommended (TABLE 1).12,13 
The prognostic value of MELD scores in patients 
with HF receiving non‑vitamin K antagonist oral 
anticoagulants remains unknown.13
In this issue of the Polish Archives of Internal 
Medicine (Pol Arch Intern Med), Szyguła ‑Jurkiewicz 
et al15 report their single ‑center experience with 
1‑year survival in ambulatory patients with end‑
‑stage HF who were placed on the heart transplant 
waiting list. The mortality rate during the study 
follow ‑up was 43.3%.15 Based on the univariate 
and multivariate logistic regression analyses, 
the authors found that the modMELD score, as 
well as serum levels of high‑sensitivity C‑reactive 
protein, sodium, and uric acid were independent 
predictors of death in the study population.15 In 
addition, they demonstrated that the modMELD 
score of more than 10 predicts HF mortality with 
a sensitivity of 82% and specificity of 77% (area 
under the receiver operating characteristic curve, 
0.868; 95% CI, 0.821–0.915).15 However, this in‑
teresting finding needs to be confirmed in future 
prospective studies.
system, upregulation of inflammatory cytokines, 
and sodium and water retention.6 Advanced HF 
may also lead to cardio hepatic abnormalities in‑
cluding congestive hepatopathy, ischemic hepati‑
tis, and cardiac cirrhosis.6
In recent years, numerous prognostic risk 
scores have been developed by multivariate sur‑
vival analyses in adult patients with HF. In these 
multivariate predictive models, relative weights 
are assigned to each parameter with the aim of 
calculating the probability that a specific event 
(ie, death) will happen in the future.11 Prognostic 
scoring systems help clinicians estimate progno‑
sis and predict therapeutic response, translating 
the result of prognostic studies to everyday clini‑
cal practice.11 Furthermore, the analysis of these 
models is fundamental for public health policy, 
comparative effectiveness research, and health 
technology assessment of therapies.11 Howev‑
er, the clinical utility of prognostic scores is not 
unlimited.1,6 The main limitation of the current 
prognostic models is the interpatient variabili‑
ty of the clinical course and progression of HF, 
which significantly impairs the adequacy of der‑
ivation samples and validation in specific patient 
cohorts.1,6 In addition, the population ‑based risk 
may not reflect individual patient risk. Although 
prognostic scales significantly correlated with sur‑
vival in large populations, their usefulness to pre‑
dict survival in individual patients with HF is gen‑
erally less clear. Most prognostic models in HF fo‑
cused on the single clinical outcome, particular‑
ly on mortality. There is evidence that prognostic 
scores may help predict death in HF patients, but 
remain less useful for the prediction of HF hos‑
pitalizations or decreased quality of life.1 The re‑
sults of meta ‑analyses and systematic reviews 
evaluating over 200 prognostic models showed 
only a moderate accuracy for predicting deaths, 
and even poorer estimation precision for predict‑
ing hospitalization or the combined endpoint of 
death from, or hospitalization for, HF.1
There are several well ‑validated prognostic 
scores frequently used to predict mortality in 
patients with advanced HF, including the Seat‑
tle Heart Failure Model (SHFM), Meta ‑Analysis 
Global Group in Chronic Heart Failure (MAGGIC) 
TABLE 1 The Model for End-stage Liver Disease (MELD) and MELD -variant scores (modified from references no. 12–15)
MELD 9.57 × ln (creatinine [mg/dl]) + 3.78 × ln (bilirubin [mg/dl]) + 11.2 × ln(INR) + 6.43
MELDNa MELD – Na (mmol/l) – (0.025 × MELD × (140 – Na [mmol/l]) + 140; Na range = 125–140 mmol/l
MELD -Na MELD + 1.59 × (135 – Na [mmol/l]); Na range = 120–135 mmol/l
MELD -XI 5.11 × ln (bilirubin [mg/dl]) + 11.76 × ln (creatinine [mg/dl]) + 9.44
modMELD If serum albumin >4.1 g/dl: 1.12  × (ln 1) + 0.378 × ln (bilirubin [mg/dl]) + 0.957 × ln (creatinine [mg/dl]) + 0.643
If serum albumin <4.1 g/dl: 1.12 × (ln [1+ (4.1 – albumin)]) + 0.378 × ln (bilirubin [mg/dl]) + 0.957 × ln (creatinine [mg/
dl]) + 0.643
iMELD MELD + (age [years] × 0.3) – (0.7 × Na [mmol/l]) + 100
Updated MELD 1.27 × ln (1 + creatinine [mg/dl]) + 0.94 × ln (1 + bilirubin [mg/dl]) + 1.66 × ln (1 + INR)
MESO (MELD / Na [mmol/l]) × 100
UKELD 5 ×{1.5 × ln(INR) + 0.3 × ln(creatinine [µmol/l]) + 0.6 × ln(bilirubin [µmol/l]) – 13 × ln (Na [mmol/l]) + 70}
Abbreviations: INR, international normalized ratio; Na, sodium
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In summary, several risk scoring systems are 
available to predict mortality in patients with 
end ‑stage HF. All of them provide additional, 
prognostic information and can be used to eval‑
uate the outcome in patients with advanced HF. 
The newly proposed, simple, and accurate prog‑
nostic model, modMELD score, seems to be a clin‑
ically useful tool in predicting survival in end‑
‑stage HF. However, further studies are required 
to better stratify and identify high ‑risk patients 
with advanced HF who would benefit from addi‑
tional, more aggressive interventions.
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